Total Return chart SAMSUNG PHARM. Co., LTD.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1,663 ^KRW	-1.07%		-1.95%	-23.54%

2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI
2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.